Merck to buy inflammatory disease drugmaker Prometheus for $10.8B

Merck & Co. has reached a deal to acquire Prometheus Biosciences for about $10.8 billion, betting an experimental drug the biotechnology company is developing will become an important new treatment for a common gut disease.